🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to announce the launch of a basket trial of MCLA-128 in pts with NRG1 fusion+ tumors. This HER2/HER3 bispecific directly addresses the oncogenic NRG1 fusion ligand. Looking forward to working with a talented group of investigators, Sai-Hong Ignatius Ou Alexander Drilon MD, etc. #Merus

Proud to present a clinical proof-of-concept for MCLA-128 in NRG1 fusion+ cancers at #Targets19! Grateful to be @sloan_kettering where rapid bench-to-bedside innovation is possible and thankful for these brave patients. Summary ⬇️. Phase 2 basket trial now enrolling Merus.

Lessons learned and future directions for genome-driven oncology, in Cancer Cell now! @yoninamg Barry S. Taylor David Hyman Toward a More Precise Future for Oncology cell.com/cancer-cell/fu…

Prospective @sloan_kettering #prostateCancer trial supports the feasibility and favorable tolerability of ultrahypofractionated regimens in combination with low dose rate #brachytherapy. Results out now in the #RedJournal #pcsm #SBRT #thisisBrachytherapy redjournal.org/article/S0360-…

Very excited to announce the Marciscano Lab Weill Cornell Medicine is (finally) opening its doors this week! We are actively recruiting for a postdoc position. Come join our stellar team of investigators! Announcement below, DM or e-mail [email protected], if interested!⚡️🧬🔬🐁💉

Thrilled to have had our SIV for #DASLHiCaP today @sloankettering. We’re honored to be the lead US site for this outstanding trial that will offer a lot to men with very high risk or biochemically recurrent #ProstateCancer. The PCCTC Christopher Sweeney, MBBS Karen Bracken Ian Davis (Bluesky @profiand)